Nike Inc (NKE) 61.47 $NKE HP’s Thrust Into 3D Printers

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nike Inc (NKE) 61.47 $NKE

HP’s Thrust Into 3D Printers Could Torch 3D Systems, Stratasys
at Investor's Business Daily - Thu Mar 31, 2:57PM CDT
The entry of HP Inc. (HPQ) into the 3D printer market is seen as creating problems for 3D Systems (DDD) and Stratasys (SSYS), causing an analyst to issue a warning about the two market leaders. While 3D Systems and Stratasys are the two largest...
GE: 31.79 (-0.04), NKE: 61.47 (-0.57), DDD: 15.47 (+0.09), SSYS: 25.92 (+0.79), HPQ: 12.32 (+0.02)

Cramer: Lessons From 2 Stocks That the Shorts Got Wrong
at The Street - Thu Mar 31, 5:12AM CDT
Lululemon and Carnival show you the dangers of underestimating a stock.
UA: 84.83 (-0.81), CCL: 52.77 (+0.40), NKE: 61.47 (-0.57), LULU: 67.71 (-0.09)

Nike Earnings Pullback Could Be A Unique Buy Opportunity
Dana Blankenhorn - Amigobulls - Thu Mar 31, 2:36AM CDT
Nike is a stock you buy and you hold. When you can get it at a discount because expectations got a little ahead of themselves, you jump on it.
UA: 84.83 (-0.81), NKE: 61.47 (-0.57)

After Mixed Earnings, is Nike (NKE) Stock a Buy, Hold, or Sell?
Maher Syed - Zacks Investment Research - Wed Mar 30, 2:33PM CDT
The company posted a beat on earnings, but missed on revenues. How should you approach NKE shares right now?
NKE: 61.47 (-0.57)

Will NIKE's (NKE) Growth Plans Keep it in Investors' Minds?
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:00PM CDT
When we speak of stocks with solid fundamentals, unprecedented growth and a splendid earnings history, one company that comes to mind is the athletic goods retailer, NIKE Inc. (NKE).
DLA: 19.14 (-0.26), NKE: 61.47 (-0.57), COLM: 60.09 (-0.84), KORS: 56.96 (+0.09)

NIKE (NKE) Breaks Through Resistance at $61.84
Comtex SmarTrend(R) - Wed Mar 30, 9:24AM CDT
Shares of NIKE (NYSE:NKE) have bullishly opened above the pivot of $61.55 today and have reached the first resistance level of $61.84. Analysts will be watching for a cross of the next upside pivot targets of $62.20 and $62.85.
NKE: 61.47 (-0.57)

Can Lululemon Continue to Compete With Nike in Athleisure?
ESTMZ - Tue Mar 29, 5:19PM CDT
Lululemon Athletica ( LULU ) Consumer Discretionary - Textiles, Apparel & Luxury Goods | Reports March 30, Before Market Opens Key Takeaways The Estimize consensus, on the other hand, is calling for EPS of $0.80, right in line with Wall...
SPY: 205.52 (-0.50), NKE: 61.47 (-0.57), LULU: 67.71 (-0.09)

Foot Locker's Chart Is Volatile, But Indicators Point Up
at The Street - Tue Mar 29, 4:21PM CDT
The company could be prepping for a major move higher. 
UA: 84.83 (-0.81), NKE: 61.47 (-0.57), FL: 64.50 (-1.24)

Steph Curry Is the Real MVP for Under Armour in China
at The Street - Tue Mar 29, 2:10PM CDT
Under Armour's growth plans rest on Stephen Curry and China. 
UA: 84.83 (-0.81), NKE: 61.47 (-0.57)

DICK's Sporting's New Utah Store Upholds Expansion Zeal
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 2:05PM CDT
Moving further ahead with its strategic initiative of expanding store base, DICK's Sporting Goods Inc. (DKS) announced plans to open a new store in Utah on Apr 8.
UA: 84.83 (-0.81), NKE: 61.47 (-0.57), DKS: 46.75 (-0.24), HZO: 19.47 (-0.01)

Here's Why Foot Locker Has Been Tapped to Join the S&P 500
at The Street - Tue Mar 29, 11:55AM CDT
Foot Locker will join the coveted S&P 500 index after a bang-up year of sales and profits, which could possibly boost its stock price more.
UA: 84.83 (-0.81), NKE: 61.47 (-0.57), FL: 64.50 (-1.24), FINL: 21.10 (-0.24)

Here's How 3-D Printing Is Transforming the Fashion Industry
at The Street - Tue Mar 29, 11:54AM CDT
By shortening the supply chain and eliminating the need for inventory, 3-D printing is shaking up the fashion industry in a significant way.
UA: 84.83 (-0.81), NKE: 61.47 (-0.57)

Time to Take Profits in Lululemon
at The Street - Tue Mar 29, 5:07AM CDT
The yoga apparel maker reports earnings Wednesday. Time to rotate into another retailer such as Nike.
NKE: 61.47 (-0.57), XRT: 46.18 (-0.06), LULU: 67.71 (-0.09)

Nike Remains A Good Investment Despite The Slight Miss On The Top Line
William Bias - Amigobulls - Tue Mar 29, 4:00AM CDT
Nike’s focus on the consumer combined with its scale, leadership, product depth and diversity serve as a recipe for long-term success.
NKE: 61.47 (-0.57)

Better Buy: Nike, Inc. vs. Under Armour
Steve Symington, The Motley Fool - Motley Fool - Mon Mar 28, 6:31PM CDT
Almost three years ago, I decided to pit two of my favorite consumer-goods stocks against one another to see which was the better buy . On one hand was Nike , a juggernaut in the sportswear and athletic footwear space. And on the other, Under...
UA: 84.83 (-0.81), NKE: 61.47 (-0.57)

3 Takeaways From Nike Inc.'s Earnings
James Sullivan, The Motley Fool - Motley Fool - Mon Mar 28, 10:00AM CDT
Under Armour  gets a lot of press as the new(er) athletic apparel company on the block, but  Nike 's third-quarter results show how its growth story is far from over. Success in China and Japan, and with its capital allocation plan, leaves Nike in...
UA: 84.83 (-0.81), NKE: 61.47 (-0.57)

The Zacks Analyst Blog Highlights: Starwood Hotels & Resorts Worldwide, Marriott International, Exxon Mobil, Chevron and NIKE
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Starwood Hotels & Resorts Worldwide, Marriott International, Exxon Mobil, Chevron and NIKE
NKE: 61.47 (-0.57), XOM: 83.59 (-0.93), CVX: 95.40 (+0.15), MAR: 71.18 (-0.37), HOT: 83.43 (-0.23)

Flex Deal And New Product Launches To Drive Nike Stock Going Forward
Nicholas Mushaike - Amigobulls - Mon Mar 28, 5:47AM CDT
The partnership will also allow Nike to minimize on excess inventory clearing costs because of Flex's shorter delivery time.
NKE: 61.47 (-0.57)

AAPL, GOOGL, NKE, UA: Jim Cramer's Views
at The Street - Mon Mar 28, 12:00AM CDT
Jim Cramer shares his views on pricing power and snap judgments. Apple, Google, Nike and Under Armour are among the stocks discussed here.
MNK: 61.28 (+1.37), VRX: 26.30 (-0.77), NKE: 61.47 (-0.57), FB: 114.10 (-0.60), MO: 62.66 (+0.08), PLKI: 52.06 (+0.28), JACK: 63.87 (-0.59), UA: 84.83 (-0.81), PM: 98.11 (-0.58), VAL: 107.02 (+0.45), DNKN: 47.17 (+0.19), RIG: 9.14 (+0.25), GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), MCD: 125.68 (-0.15), GOOGL: 762.90 (-5.44), SHW: 284.67 (+0.24), KKD: 15.59 (+0.16), AAPL: 108.99 (-0.57)

Finish Line Is Racing Against Sports Retail Headwinds
at The Street - Thu Mar 24, 3:18PM CDT
The retailer rose today, but the road ahead could be rocky based on weak guidance. 
NKE: 61.47 (-0.57), M: 44.09 (-0.01), FINL: 21.10 (-0.24)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles